Sorry, you need to enable JavaScript to visit this website.
Skip to main content

User menu

  • Sign in
  • Register

Main menu

  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources
Pfizer Home
  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources

News

  • News Archive

Search form

This site is intended only for healthcare professionals resident in the United Kingdom

Key Summary Of The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Published by: By Pfizer staff
Date of publishing: 12th Oct 2017

Although the true incidence is unknown, conservative estimates indicate that sepsis is a leading cause of mortality and critical illness worldwide.1 The reported incidence of sepsis is increasing likely reflecting aging populations with more comorbidities and greater recognition.1 Furthermore, there is increasing awareness that patients who survive sepsis often have long-term physical, psychological, and cognitive disabilities with significant health care and social implications.1

Since the definitions for sepsis and septic shock were last revised in 2001, considerable advances have since been made into the pathobiology (changes in organ function, morphology, cell biology, biochemistry, immunology, and circulation), management, and epidemiology of sepsis, suggesting the need for re-examination.1Multiple definitions and terminologies are currently in use for sepsis, septic shock, and organ dysfunction, leading to discrepancies in reported incidence and observed mortality. Previous definitions included an excessive focus on inflammation, the misleading model that sepsis follows a continuum through severe sepsis to shock, and inadequate specificity and sensitivity of the systemic inflammatory response syndrome (SIRS) criteria.1

A taskforce of 19 critical care, infectious disease, surgical, and pulmonary specialists expertise in sepsis pathobiology, clinical trials, and epidemiology was convened by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. They evaluated and updated definitions and clinical criteria for sepsis and septic shock through meetings, Delphi processes, analysis of electronic health record databases, and voting, followed by circulation to international professional societies, requesting peer review and endorsement by 31 societies.1

 

The taskforce concluded the term severe sepsis was redundant. They recommended that sepsis should be defined as ‘life-threatening organ dysfunction caused by a dysregulated host response to infection.’ For clinical operationalisation, organ dysfunction can be represented by an increase in the Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score of 2 points or more, which is associated with an in-hospital mortality greater than 10%. Septic shock should be defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia. This combination is associated with hospital mortality rates greater than 40%. In out-of-hospital, emergency department, or general hospital ward settings, adult patients with suspected infection can be rapidly identified as being more likely to have poor outcomes typical of sepsis if they have at least 2 of the following clinical criteria that together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate of 22/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less.1

In conclusions, the experts advised that these updated definitions (Sepsis-3) and clinical criteria should replace previous definitions, offer greater consistency for epidemiologic studies and clinical trials, and facilitate earlier recognition and more timely management of patients with sepsis or at risk of developing sepsis.1

 

 

Reference: Singer, M., The Third International Consensus Definitions for Sepsis and Septic Shock, JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287 accessed from: http://jamanetwork.com/journals/jama/fullarticle/2492881 on 24/08/17

 

 Date of Preparation: March 2018  PP-GEP-GBR-1003

Pfizer Home
  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources

News

  • News Archive

Janrain Capture

  • Register / Sign in

Footer menu

  • Report Adverse Events
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Pfizer.co.uk

Copyright footer block

© 2018 Pfizer Limited. All rights reserved. PP-PFE-GBR-1078. Date of preparation: May 2018.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration  number GB201048427
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For healthcare professionals only*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select ‘No’, you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer’s prescription medicines.

*The ABPI Code definition of healthcare professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-GIP-GBR-3015 March 2018

YesNo
Your login attempt failed. Please try again.

{* message_withExistingAccount *}

{* loginWidget *}

{* message_joinNow *}

{* message_joinNowText *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* traditionalSignIn_createButton *}

{* message_signIn *}

Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* loginWidget *}
{* message_useAnotherAccount *}
Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* message_useAnotherAccount *}

{* message_registeringThankYou *}

{* message_confirmEmailSent *}

{* message_close *}

{* message_confirmTraditionalInformation *} {* message_alreadyHaveAccount *}

* Required Information

{* #registrationForm *} {* salutation *} {* givenName *} {* familyName *} {* email *} {* designation_name *} {* designation_specialty *} {* designation_specialty2 *} {* designation_specialty_json *} {* primaryAddress_workplace *} {* primaryAddress_postalCode *} {* phoneNumber_work *} {* license_number *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* acknowledgement_professional *} {* acknowledgement_consent *} {* acknowledgement_terms *}
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
{* hidden_programType *} {* hidden_campaign *} {* hidden_siteId *} {* hidden_preferredLanguage *} {* hidden_residencyCountry *}

PP-PFE-GBR-1083. Date of preparation May 2018
{* backButton *}
{* createAccountButton *}
{* /registrationForm *}
{*#postLoginAcceptanceForm*}

{* message_legalText *}

{* postLoginAcceptanceButton *}
{*/postLoginAcceptanceForm*}

{* message_emailPasswordResetInstructions *}

{* #forgotPasswordForm *} {* traditionalSignIn_emailAddress *}
{* backButton *}
{* forgotPassword_sendButton *}
{* /forgotPasswordForm *}

{* message_emailPasswordResetSent *}

{* message_close *}
{* mergeAccounts *}
{* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *}
{* backButton *}
{* traditionalSignIn_signInButton *}
{* /tradAuthenticateMergeForm *}